XML 82 R66.htm IDEA: XBRL DOCUMENT
v2.4.1.9

SEGMENT INFORMATION (Major Customers) (Details) | 12 Months Ended
--- | ---
Sep. 30, 2014 | Sep. 30, 2013
Arrowhead [Member] | Sales [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 12.10%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_ArrowheadMember | 0.40%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_ArrowheadMember
Arrowhead [Member] | Accounts Receivable [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 18.50%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_ArrowheadMember | 4.60%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_ArrowheadMember
Principia Biopharma [Member] | Sales [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 8.70%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_PrincipiaBiopharmaMember | 0.40%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_PrincipiaBiopharmaMember
Principia Biopharma [Member] | Accounts Receivable [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 8.40%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_PrincipiaBiopharmaMember | 7.10%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_PrincipiaBiopharmaMember
Boehringer Ingelheim [Member] | Sales [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 5.90%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_BoehringerIngelheimMember | 6.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_BoehringerIngelheimMember
Boehringer Ingelheim [Member] | Accounts Receivable [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 2.50%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_BoehringerIngelheimMember | 2.60%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_BoehringerIngelheimMember
Pfizer, Inc. [Member] | Sales [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 1.70%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_MajorCustomerTwoMember | 1.50%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_SalesMember / us-gaap_MajorCustomersAxis = basi_MajorCustomerTwoMember
Pfizer, Inc. [Member] | Accounts Receivable [Member] |  |
Revenue, Major Customer [Line Items] |  |
Concentration risk, percentage | 4.90%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_MajorCustomerTwoMember | 3.30%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_MajorCustomersAxis = basi_MajorCustomerTwoMember

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_EntityWideRevenueMajorCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_MajorCustomersAxis=basi_ArrowheadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=basi_BoehringerIngelheimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=basi_MajorCustomerTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=basi_PrincipiaBiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |